<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568477</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-518-HEE-0200-S</org_study_id>
    <secondary_id>EudraCT-number: 2006-006137-41</secondary_id>
    <nct_id>NCT00568477</nct_id>
  </id_info>
  <brief_title>Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation</brief_title>
  <acronym>Rituximab 2006</acronym>
  <official_title>Prospective, Randomized, Open, 2-arm National Multi-center Study to Evaluate the Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Humboldt-Universität zu Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Erlangen-Nürnberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Transplantationszentrum Köln-Merheim</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Regensburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the benefit of rituximab in patients with CAN with histologically proven C4d&#xD;
      deposits and/or plasma cell and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, open, 2-arm, national multi-center study to evaluate&#xD;
      the value of rituximab in humoral chronic rejection after renal transplantation in&#xD;
      approximately 150-200 patients (75-100 patients each group).&#xD;
&#xD;
      All biopsies will be analysed by Prof. Groene (Heidelberg) and the results immediately&#xD;
      communicated to the central managing unit (Munich). Upon receipt, patients with biopsy proven&#xD;
      CAN with C4d+ and/or plasma-cells and/or B-lymphocytes within the last 4 weeks before&#xD;
      inclusion (centrally confirmed), fulfilling the inclusion/exclusion criteria, will be&#xD;
      randomized 1:1 into one of the 2 groups:&#xD;
&#xD;
      Arm 1: Treatment with rituximab Arm 2: Treatment without rituximab Recruitment will last for&#xD;
      approximately one year. All patients will be treated with baseline medication of Tacrolimus,&#xD;
      MMF, steroids (optional, with same dose as given before study entry) and ACE-inhibitor or&#xD;
      AT1-receptor-antagonist. A single dose of 100 mg Methylprednisolone i.v. will be given at&#xD;
      baseline (day 0) in both groups (in the rituximab group 30 min before start of the rituximab&#xD;
      infusion).&#xD;
&#xD;
      Each patient will be followed for 1 year within protocol, with study visits at 1,3,7 and 14&#xD;
      days (rituximab group), 3, 6 and 12 months followed by a follow-up period of 1 year with a&#xD;
      study visit at 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lacking recruitment&#xD;
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective: To evaluate the benefit of Rituximab in patients with CAN with histologically proven C4d deposits and/or B-Lymphocyte (CD20+ cells) infiltration of their grafts. Secondary objectives: Renal function at 1 year</measure>
    <time_frame>Graft survival at 1 and 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function at 1 year</measure>
    <time_frame>Graft survival at 1 and 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Grafting</condition>
  <condition>Renal Transplantation</condition>
  <condition>Transplantation, Kidney</condition>
  <condition>Chronic Allograft Nephropathy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment without rituximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MabThera</intervention_name>
    <description>Rituximab (MabThera):&#xD;
375 mg/m² as IV infusions over &gt;=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Renal allograft recipients at least 1 year after transplantation with GFR &gt; 25 ml/min&#xD;
             x 1,73m2 (MDRD)&#xD;
&#xD;
          -  Single organ recipients of renal allograft&#xD;
&#xD;
          -  Patients who have provided informed consent&#xD;
&#xD;
          -  Patients who are &gt;= 18 years of age&#xD;
&#xD;
          -  Patients who have biopsy proven CAN with C4d+ deposits and/or plasma-cells and/or&#xD;
             B-lymphocytes within the last 4 weeks before inclusion&#xD;
&#xD;
          -  Patients who are treated with ACE/AT1 Blocker more than 1 week before inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who suffer from HIV infection&#xD;
&#xD;
          -  Patients with a history of Hepatitis B&#xD;
&#xD;
          -  Patients with Hepatitis C (active/chronic)&#xD;
&#xD;
          -  Patients who have a contraindication for the use of rituximab, such as leukopenia or&#xD;
             experienced infusion-related adverse events to former antibody treatment&#xD;
&#xD;
          -  Patients who showed signs of acute cellular rejection in the biopsy&#xD;
&#xD;
          -  Patient has a malignancy or history of malignancy within the last 5 years, except&#xD;
             non-metastatic basal or squamous cell carcinoma of the skin that has been treated&#xD;
             successfully.&#xD;
&#xD;
          -  Patient has a systemic infection requiring treatment.&#xD;
&#xD;
          -  Female patients who are pregnant or lactating&#xD;
&#xD;
          -  Patients who have any form of substance abuse, psychological illness or any other&#xD;
             condition, which, in the opinion of the investigator, may interfere with the patient's&#xD;
             ability to understand the requirements of the study.&#xD;
&#xD;
          -  Patients who have a proteinuria &gt;4g/24h&#xD;
&#xD;
          -  Patient is unlikely to comply with the visits scheduled in the protocol.&#xD;
&#xD;
          -  Patient is simultaneously participating in another investigational drug study or has&#xD;
             participated in such study within 28 days before entry in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Heemann, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technical University of Munich, Klinikum rechts der Isar; Münchner Studienzentrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Technical University of Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>September 30, 2009</last_update_submitted>
  <last_update_submitted_qc>September 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2009</last_update_posted>
  <responsible_party>
    <name_title>Univ.-Prof. Dr. med. Dr. h.c. Uwe Heemann</name_title>
    <organization>Technical University of Munich, Klinikum rechts der Isar</organization>
  </responsible_party>
  <keyword>Rituximab, Heemannn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

